Royal Bank of Canada’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.2M | Buy |
606,707
+562,403
| +1,269% | +$16M | ﹤0.01% | 1494 |
|
|
2025
Q1 | $1.31M | Buy |
44,304
+12,241
| +38% | +$361K | ﹤0.01% | 2963 |
|
|
2024
Q4 | $932K | Sell |
32,063
-19,519
| -38% | -$567K | ﹤0.01% | 3182 |
|
|
2024
Q3 | $2.37M | Buy |
51,582
+41,473
| +410% | +$1.91M | ﹤0.01% | 2533 |
|
|
2024
Q2 | $413K | Buy |
10,109
+6,970
| +222% | +$285K | ﹤0.01% | 3801 |
|
|
2024
Q1 | $80K | Sell |
3,139
-20,805
| -87% | -$530K | ﹤0.01% | 4877 |
|
|
2023
Q4 | $217K | Buy |
23,944
+11,856
| +98% | +$107K | ﹤0.01% | 4523 |
|
|
2023
Q3 | $77K | Buy |
12,088
+4,414
| +58% | +$28.1K | ﹤0.01% | 5064 |
|
|
2023
Q2 | $85K | Buy |
7,674
+3,280
| +75% | +$36.3K | ﹤0.01% | 5015 |
|
|
2023
Q1 | $67K | Sell |
4,394
-2,891
| -40% | -$44.1K | ﹤0.01% | 5084 |
|
|
2022
Q4 | $161K | Buy |
7,285
+6,043
| +487% | +$134K | ﹤0.01% | 4607 |
|
|
2022
Q3 | $20K | Buy |
1,242
+868
| +232% | +$14K | ﹤0.01% | 5655 |
|
|
2022
Q2 | $5K | Sell |
374
-2,438
| -87% | -$32.6K | ﹤0.01% | 6197 |
|
|
2022
Q1 | $52K | Sell |
2,812
-5,113
| -65% | -$94.6K | ﹤0.01% | 5583 |
|
|
2021
Q4 | $189K | Buy |
7,925
+135
| +2% | +$3.22K | ﹤0.01% | 4877 |
|
|
2021
Q3 | $192K | Buy |
7,790
+944
| +14% | +$23.3K | ﹤0.01% | 4713 |
|
|
2021
Q2 | $169K | Sell |
6,846
-277
| -4% | -$6.84K | ﹤0.01% | 4750 |
|
|
2021
Q1 | $155K | Buy |
7,123
+3,798
| +114% | +$82.6K | ﹤0.01% | 4663 |
|
|
2020
Q4 | $85K | Buy |
+3,325
| New | +$85K | ﹤0.01% | 4885 |
|